selected publications
- A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia & lymphoma. 2022 Academic Article GET IT
-
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
American journal of hematology.
2022
Letter
GET IT
Times cited: 13 -
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms.
American journal of hematology.
2021
Letter
GET IT
Times cited: 12 - Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. Leukemia & lymphoma. 2021 Comment GET IT
-
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
Leukemia & lymphoma.
2021
Academic Article
GET IT
Times cited: 10 -
Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
Leukemia & lymphoma.
2021
Academic Article
GET IT
Times cited: 5 -
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
Transplantation and cellular therapy.
2021
Academic Article
GET IT
Times cited: 11 -
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
American journal of hematology.
2021
Letter
GET IT
Times cited: 4 -
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia.
Blood.
2021
Academic Article
GET IT
Times cited: 35 -
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Blood advances.
2021
Academic Article
GET IT
Times cited: 64 -
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.
Blood advances.
2020
Academic Article
GET IT
Times cited: 90 -
Single-cell mutation analysis of clonal evolution in myeloid malignancies.
Nature.
2020
Academic Article
GET IT
Times cited: 192 -
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
Blood advances.
2020
Academic Article
GET IT
Times cited: 65 -
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Cancer discovery.
2020
Academic Article
GET IT
Times cited: 17 -
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
The Lancet. Haematology.
2020
Review
GET IT
Times cited: 51 -
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Leukemia research.
2020
Academic Article
GET IT
Times cited: 21 -
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
Leukemia research.
2020
Academic Article
GET IT
Times cited: 13 -
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy.
JCO precision oncology.
2020
Academic Article
GET IT
Times cited: 4 -
Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification.
Haematologica.
2020
Editorial Article
GET IT
Times cited: 3 -
Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
Leukemia & lymphoma.
2019
Review
GET IT
Times cited: 2 -
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
2019
GET IT
Times cited: 46 -
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.
Current oncology reports.
2019
Review
GET IT
Times cited: 60 -
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
Haematologica.
2018
Academic Article
GET IT
Times cited: 10 -
Clinical Development of PD-1 Blockade in Hematologic Malignancies.
Cancer journal (Sudbury, Mass.).
2018
Review
GET IT
Times cited: 11 -
Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma.
2017
GET IT
Times cited: 7 - Link between flu vaccines and narcolepsy still needs investigating. BMJ (Clinical research ed.). 2017 Letter GET IT
-
Down for the count in acute myeloid leukemia.
Blood.
2016
Comment
GET IT
Times cited: 2 -
Genome editing a mouse locus encoding a variant histone, H3.3B, to report on its expression in live animals.
Genesis (New York, N.Y. : 2000).
2014
Academic Article
GET IT
Times cited: 6 -
Tumors metastatic to the heart.
Circulation.
2013
Review
GET IT
Times cited: 148 -
Hira-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells.
Cell.
2013
Academic Article
GET IT
Times cited: 191 -
Distinct factors control histone variant H3.3 localization at specific genomic regions.
Cell.
2010
Academic Article
GET IT
Times cited: 919 -
New functions for an old variant: no substitute for histone H3.3.
Current opinion in genetics & development.
2010
Review
GET IT
Times cited: 124 -
Epigenetics: a landscape takes shape.
Cell.
2007
Review
GET IT
Times cited: 1763 -
Distinct RNA motifs are important for coactivation of steroid hormone receptors by steroid receptor RNA activator (SRA).
Proceedings of the National Academy of Sciences of the United States of America.
2002
Academic Article
GET IT
Times cited: 140